Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Loses Fight To Persuade NICE Of Xalkori’s Cost-Effectiveness

This article was originally published in The Pink Sheet Daily

Executive Summary

Pfizer says that it won’t challenge NICE’s final rejection of Xalkori on cost-effectiveness and survival uncertainty grounds.

You may also be interested in...



As Global Payers Become Monopolies, Biopharma Need To Demonstrate Value Earlier – AusBiotech Conference

Biopharma companies should define value propositions early and have a case for value differentiation at the discovery stage if they want to make a case to payers.

Product Approvals In Brief: Xalkori Gets Full Approval, H5N1 Flu Vaccine Approved

Pfizer gains full approval for its lung cancer treatment Xalkori, following accelerated approval in 2011; also updates on ID Biomedical’s adjuvanted H5N1 flu vaccine; a new indication for Bayer/Onyx’s cancer treatment Nexavar; a new formulation for Merck’s antifungal Noxafil; and BTG’s new varicose vein product Varithena.

Xalkori And Inlyta: NICE Pans Two Pfizer Oncology Drugs In Two Days

Britain’s NICE has rejected Pfizer’s Xalkori (crizotinib) for lung cancer and Inlyta (axitinib) for kidney carcinoma within two days of each other, putting drug discounts back in the spotlight.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS076109

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel